SCHEMBL6415574

SCHEMBL6415574

FC12CC(C1)C2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL812407 0.79 GRIN2D (0.44)
Water SCHEMBL27637741 0.76 GRIN2D (0.42)
SCHEMBL2574454 0.65 GRIN2D (0.33)
SCHEMBL278088 0.65
SCHEMBL22996639 0.63
SCHEMBL6406821 0.63
SCHEMBL14759415 0.61
SCHEMBL705721 0.61
SCHEMBL17097898 0.60
SCHEMBL18171379 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022266363-A1 PROTEASE INHIBITORS FOR THE TREATMENT OF CORONAVIRUS INFECTIONS THE SCRIPPS RESEARCH INSTITUTE (US) 2022-12-22 WO claimed
US-12570625-B2 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof NOVARTIS AG (CH) 2026-03-10 US disclosed
US-20250381206-A1 INVARIANT NATURAL KILLER T-CELL ACTIVATORS DECIDUOUS THERAPEUTICS, INC. (US) 2025-12-18 US disclosed
WO-2025106751-A1 COMBINATIONS OF A POTASSIUM CHANNEL ACTIVATOR AND AN MC4R AGONIST AND RELATED METHODS OF USE RHYTHM PHARMACEUTICALS, INC. (US) 2025-05-22 WO disclosed
CN-119241408-A Trifluoro methyl sulfide molecule as HIF2a inhibitor 维眸生物科技(浙江)有限公司 2025-01-03 CN disclosed
US-20240383905-A1 FGFR INHIBITORS AND METHODS OF USE THEREOF 3H PHARMACEUTICALS CO., LTD. (CN) 2024-11-21 US disclosed
US-20240252473-A1 Sulfoximines as inhibitors of NaV1.8 GRUENENTHAL GMBH (DE) 2024-08-01 US disclosed
US-20240116910-A1 Heterocycles as WIP1 Inhibitors PMV PHARMACEUTICALS, INC. 2024-04-11 US disclosed
US-20240101589-A1 INHIBITORS OF METTL3 EVOTEC INTERNATIONAL GMBH (DE) 2024-03-28 US disclosed
CN-114423741-B aryl-N-aryl derivatives for the treatment of RNA viral infections ABIVAX公司 2023-11-07 CN disclosed
US-20200231556-A1 PREPARATION OF SUBSTITUTED 3-ARYL-5-TRIFLUOROMETHYL-1,2,4-OXADIAZOLES BASF SE (DE) 2020-07-23 US disclosed
US-20050053552-A1 Phase shift colloids as ultrasound contrast agents QUAY STEVEN C (US) 2005-03-10 US disclosed
US-6569404-B1 Aqueous colloidal suspension, dispersed phase is gas microbubbles of perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane or sulfur hexafluoride; fluorinated amphiphile for stabilizing microbubbles AMERSHAM HEALTH A/S (NO) 2003-05-27 US disclosed
US-6245319-B1 Colloidal dispersions of perfluoropentane SONUS PHARMACEUTICALS, INC. 2001-06-12 US disclosed
EP-0680341-B1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMA INC (US) 2001-05-09 EP disclosed
EP-1038535-A2 Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents SONUS PHARMACEUTICALS, INC. (US) 2000-09-27 EP disclosed
US-5876696-A Composition comprising a fluorine containing surfactant and perfluoropentane for ultrasound SONUS PHARMACEUTICALS, INC. (US) 1999-03-02 US disclosed
US-5558853-A WATER IMMISCIBLE FLUORINE COMPOUND SONUS PHARMACEUTICALS (US) 1996-09-24 US disclosed
EP-0680341-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1995-11-08 EP disclosed
WO-1994016739-A1 PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS SONUS PHARMACEUTICALS, INC. (US) 1994-08-04 WO disclosed